Juvenile arthritis

1. High-Yield Summary

• Definition: Juvenile Idiopathic Arthritis (JIA) encompasses a heterogeneous group of chronic inflammatory arthritides of unknown etiology presenting before 16 years of age and persisting for a minimum of 6 consecutive weeks, with exclusion of other recognized pediatric disorders.
• Subtype Distribution: Classified according to the International League of Associations for Rheumatology (ILAR) criteria into seven categories: Oligoarthritis (most common, 50% to 60%), Polyarthritis (RF-negative and RF-positive), Systemic JIA (sJIA), Enthesitis-Related Arthritis (ERA), Psoriatic Arthritis, and Undifferentiated Arthritis.
• Silent Threat: Asymptomatic chronic anterior uveitis occurs in up to 20% of children with oligoarthritis (highest risk in ANA-positive females under 6 years of age); routine scheduled slit-lamp biomicroscopy is mandatory to avert irreversible visual loss.
• Orthopaedic Manifestations: Persistent synovial hyperemia drives asymmetric accelerated bone maturation, early physeal closure, leg-length discrepancies (LLDs), angular deformities (genu valgum, ankle valgus), micrognathia, and cervical spine subluxation.
• Modern Therapeutic Paradigm: Early aggressive treatment-to-target protocols utilizing intra-articular corticosteroid injections (triamcinolone hexacetonide), conventional synthetic DMARDs (methotrexate), and biologic agents (TNF inhibitors, IL-6 inhibitors, IL-1 inhibitors) have transformed prognosis, shifting orthopaedic intervention from salvage arthroplasty toward deformity prevention, guided growth, and soft-tissue contracture correction.

2. Anatomy

The structural vulnerability of the juvenile skeleton in chronic arthritis relates directly to the hypervascularity of developing epiphyses, the proximity of open growth plates (physes) to synovial reflections, and the distinct capsuloligamentous architecture across affected joints.

Articular Cartilage and Synovial Reflections: In pediatric joints, synovial tissue extends directly to the perichondrial ring of Lacroix and the groove of Ranvier. Chronic synovial proliferation (pannus) causes juxta-articular hypervascularity that directly stimulates the adjacent physis, leading to localized epiphyseal enlargement (ballooning) and accelerated longitudinal growth in early stages, followed by premature, asymmetric physeal closure in late disease.

Cervical Spine Anatomy: Synovitis of the atlanto-odontoid synovial bursa, transverse atlantal ligament, and apophyseal facet joints can lead to atlantoaxial subluxation (AAS), cranial settling (basilar invagination), and subaxial subluxation. The vertebral artery is at risk in the suboccipital triangle (traversing the transverse foramen of C1 to enter the foramen magnum) during severe destabilization or operative fusion.

Hip Joint and Vascular Corridors: The blood supply to the pediatric capital femoral epiphysis enters via lateral retinacular vessels branches of the medial femoral circumflex artery running along the femoral neck beneath the capsule. Proliferative synovitis creates increased intra-articular capsular pressure, predisposing to capital femoral epiphyseal avascular necrosis (AVN). Surgical exposure via anterior (Smith-Petersen) or anterolateral (Watson-Jones) approaches must preserve the ascending branch of the lateral femoral circumflex vessels and prevent traction on the femoral nerve.

Knee and Popliteal Neurovascular Space: Knee synovitis preferentially expands into the suprapatellar pouch and posterior popliteal recesses. Popliteal cysts (Baker cysts) can dissect between the medial head of the gastrocnemius and the semimembranosus tendon. The tibial nerve and popliteal artery run in close proximity to the posterior capsule and are susceptible to stretch injury when correcting longstanding fixed flexion contractures.

3. Pathogenesis

Juvenile Idiopathic Arthritis represents a spectrum of complex autoimmune and autoinflammatory conditions triggered by environmental exposures in genetically susceptible pediatric hosts.

Immunologic Dysregulation:

• Autoimmune Phenotypes (Oligoarticular, Polyarticular, ERA): Driven by aberrant adaptive immune responses. Antigen-presenting cells express specific human leukocyte antigen (HLA) class I (HLA-B27 in ERA) and class II alleles (HLA-DRB1*08, HLA-DRB1*11, and HLA-DQB1*04 in oligoarticular JIA). Autoreactive CD4+ T helper cells (Th1 and Th17) release pro-inflammatory cytokines, specifically interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), interleukin-17 (IL-17), and interleukin-21, stimulating synovial fibroblasts and macrophage activation.
• Autoinflammatory Phenotype (Systemic JIA): Dominated by dysregulated innate immunity rather than antigen-specific T-cell autoimmunity. Hyperactivation of monocytes, macrophages, and neutrophils results in massive secretion of interleukin-1 (IL-1beta, IL-18), interleukin-6 (IL-6), and S100 alarmins (calprotectin / S100A8/A9 and S100A12). This inflammatory cascade accounts for systemic fevers, evanescent rashes, polyserositis, and the life-threatening risk of Macrophage Activation Syndrome (MAS).

Articular Destruction and Physeal Alteration: Proliferating synovial lining cells form a vascularized invasive pannus that secretes matrix metalloproteinases (MMP-1, MMP-3, MMP-13) and aggrecanases (ADAMTS-4, ADAMTS-5), cleaving type II collagen and proteoglycans in hyaline cartilage. Receptor activator of nuclear factor kappa-B ligand (RANKL) upregulation drives osteoclastogenesis, causing subchondral bone erosions and localized periarticular osteopenia.

4. Natural History

Epidemiology: JIA has an annual incidence of 2 to 20 cases per 100,000 children and a prevalence of approximately 16 to 150 per 100,000. Females are predominantly affected in oligoarticular (3:1) and RF-negative polyarticular JIA (3:1 to 4:1), whereas ERA demonstrates a male predilection (2:1 to 3:1), and systemic JIA exhibits equal gender distribution. Peak age of onset is 1 to 3 years for oligoarticular JIA and biphasic for polyarthritis (early peak at 2 to 4 years, second peak at 10 to 14 years).

Clinical Evolution Without Intervention: In the pre-biologic era, untreated or poorly controlled JIA resulted in progressive articular destruction, secondary joint ankylosis (particularly the carpus, tarsus, and cervical facets), severe growth retardation from chronic systemic inflammation and glucocorticoid toxicity, and visual loss in 10% to 30% of uveitis cases. Orthopaedic sequelae included progressive limb-length discrepancies, fixed flexion deformities of hips and knees, severe retrognathia from temporomandibular joint destruction, and accelerated need for early total joint replacement.

Modern Prognosis: Contemporary early intervention with targeted synthetic and biologic disease-modifying antirheumatic drugs (DMARDs) induces clinically inactive disease or remission off medications in greater than 50% to 70% of patients, substantially decreasing joint destruction and the necessity for destructive surgical salvage.

5. Clinical Presentation

History

• Onset & Joint Complaints: Insidious joint swelling, stiffness, and antalgic limp without trauma or acute mechanical cause. Symptoms are characteristically worse in the morning upon waking or following prolonged resting (the “gelling” phenomenon), improving with gentle movement throughout the day.
• Young Children & Toddlers: Rarely complain of discrete pain; parents commonly report irritability, regression of motor developmental milestones (e.g., reverting to crawling from walking), or refusing to bear weight in the morning.
• Systemic Symptoms (sJIA): Daily high-spiking quotidian fevers (characteristically late afternoon/evening, returning to normal or subnormal baseline), accompanied by an evanescent, non-pruritic, salmon-pink macular or maculopapular rash prominent on the trunk and proximal extremities during febrile spikes.
• Extra-Articular Review: Red eye, eye pain, or photophobia (acute symptomatic uveitis in ERA), or completely asymptomatic eye involvement (chronic anterior uveitis in oligoarthritis). Inquire about psoriasis, dactylitis (“sausage digit”), buttock pain, inflammatory bowel disease symptoms, and family history of spondyloarthritis.

Physical Exam

A systematic musculoskeletal examination should appraise active and passive joint range of motion, swelling, warmth, tenderness, alignment, and leg-length equality.

6. Imaging and Diagnostic Studies

Radiographic Evaluation (Plain Radiographs):

• Standard Views: Bilateral comparative AP and lateral views of involved joints (e.g., weight-bearing AP/lateral of knees, pelvis AP with frog-leg lateral of hips, PA/lateral of wrists). Bilateral views are essential in pediatric patients to assess subtle asymmetric physeal development and epiphyseal overgrowth.
• Early Radiographic Findings: Soft-tissue swelling, periarticular osteopenia, accelerated epiphyseal ossification, and enlargement of the epiphysis adjacent to the inflamed joint (ballooning).
• Late Radiographic Findings: Symmetrical joint space narrowing, subchondral bone erosions, growth arrest lines, premature physeal fusion, joint subluxation, and articular ankylosis (notably carpal or tarsal fusion).
• Cervical Spine Radiographs: AP, open-mouth odontoid, and lateral flexion/extension views are indicated in polyarticular and longstanding JIA, particularly prior to endotracheal intubation. An anterior atlanto-dens interval (AADI) exceeding 4 mm in a pediatric patient indicates transverse ligament laxity and atlantoaxial instability.

Advanced Imaging Modalities:

• Magnetic Resonance Imaging (MRI): Most sensitive modality for early detection of inflammatory pathology. Pre- and post-gadolinium contrast T1-weighted fat-suppressed sequences demonstrate active synovial proliferation (synovitis) and synovial enhancement. Fat-suppressed T2 and STIR sequences highlight bone marrow edema (a harbinger of impending bone erosion), cartilage loss, and tenosynovitis. Dynamic contrast-enhanced MRI can quantify synovial perfusion and monitor response to medical therapy. MRI of the sacroiliac joints (coronal oblique STIR/T1) is the gold standard for diagnosing early sacroiliitis in ERA before radiographic changes appear.
• Musculoskeletal Ultrasound (MSUS): Highly sensitive, non-invasive, radiation-free bedside tool. High-frequency grayscale ultrasound differentiates intra-articular joint effusion from proliferative synovial hypertrophy, while Power Doppler (PD) assesses vascularity and active hyperemia. Ultrasound is also invaluable for real-time guidance during intra-articular corticosteroid injections.

Laboratory Studies:

• Inflammatory Markers: Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are typically elevated in systemic JIA and polyarthritis, but can be entirely normal in up to 50% of children with oligoarthritis. Normal ESR/CRP does not rule out JIA.
• Antinuclear Antibodies (ANA): Positive in 65% to 85% of oligoarthritis patients. ANA does not correlate with joint disease severity but serves as the paramount predictive biomarker for asymptomatic chronic anterior uveitis.
• Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (anti-CCP): Positivity defines RF-positive polyarticular JIA (approximately 5% of all JIA). Associated with late childhood onset, erosive course, rheumatoid nodules, and poor functional prognosis mirroring adult rheumatoid arthritis.
• HLA-B27: Associated with Enthesitis-Related Arthritis, male sex, axial involvement, and acute anterior uveitis.
• Arthrocentesis / Synovial Fluid Analysis: Clear or cloudy, straw-colored fluid with white blood cell count typically 5,000 to 50,000 cells/mcL (predominantly neutrophils), low viscosity, and negative Gram stain and cultures. Primary utility is ruling out septic arthritis and crystal-induced arthropathy.

7. Classification

The International League of Associations for Rheumatology (ILAR) consensus classification establishes mutually exclusive categories based on clinical and laboratory features during the first 6 months of disease. This classification standardizes clinical communication and directs tailored pharmacotherapy.

8. Treatment

Modern management of JIA requires a coordinated multidisciplinary approach uniting pediatric rheumatology, orthopaedic surgery, physical and occupational therapy, and pediatric ophthalmology. The primary therapeutic objective is achieving clinical remission or minimal disease activity to halt joint damage, preserve normal skeletal growth, and maintain full physical function.

Medical / Nonoperative Management

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Naproxen (10 to 20 mg/kg/day divided twice daily), ibuprofen (30 to 40 mg/kg/day divided three or four times daily), or meloxicam (0.25 mg/kg/day). Provide rapid symptomatic relief of pain and morning stiffness, but do not alter disease progression or prevent radiologic destruction. Rarely adequate as monotherapy except as short-term bridge therapy.
• Intra-Articular Corticosteroid Injections (IACI): Triamcinolone hexacetonide (THA, 1 mg/kg for large joints such as knees, up to 40 mg maximum per joint) is the preferred agent due to significantly longer remission duration and lower relapse rates compared with triamcinolone acetonide (TA). First-line therapy for active oligoarticular JIA. Ultrasound guidance enhances accuracy and minimizes subcutaneous fat atrophy.
• Conventional Synthetic DMARDs (csDMARDs): Methotrexate (MTX) is the gold-standard anchor csDMARD, administered at 10 to 15 mg/m2 body surface area once weekly (or 0.5 mg/kg/week, max 25 mg/week) with daily folic acid supplementation (1 mg/day). Subcutaneous administration is preferred over oral due to superior bioavailability and fewer gastrointestinal side effects at doses >=15 mg/m2. Indicated for polyarthritis, extended oligoarthritis, or persistent oligoarthritis failing IACI. Leflunomide or sulfasalazine (particularly in ERA) serve as alternative synthetic agents.
• Biologic DMARDs (bDMARDs) – TNF Inhibitors: Etanercept (0.8 mg/kg/week SC), Adalimumab (20 mg every 2 weeks for 15 to <30 kg, 40 mg every 2 weeks for >=30 kg), or Infliximab. First-line biologics for non-systemic polyarthritis, active sacroiliitis, and extended oligoarthritis. Adalimumab is preferred if concurrent chronic anterior uveitis is present.
• Biologic DMARDs (bDMARDs) – IL-6 Receptor Antagonist: Tocilizumab (8 mg/kg IV every 2 weeks or SC weekly for >=30 kg). First-line biologic for systemic JIA and refractory polyarticular JIA.
• Biologic DMARDs (bDMARDs) – IL-1 Inhibitors: Anakinra (recombinant IL-1 receptor antagonist, 1 to 2 mg/kg/day SC) and Canakinumab (monoclonal anti-IL-1beta, 4 mg/kg SC every 4 weeks). First-line therapy for systemic JIA to resolve systemic inflammation and prevent secondary MAS.
• Biologic DMARDs (bDMARDs) – T-Cell Costimulation Modulator: Abatacept (selective CTLA-4-Ig) is an effective alternative for refractory polyarticular disease.
• Physical and Occupational Therapy: Daily range-of-motion routines, low-impact muscle strengthening (swimming, cycling), dynamic stretching to prevent flexion contractures, and custom resting nighttime extension orthoses for knee and wrist joints.

Operative Management

Due to advances in targeted biologic therapy, the need for extensive open orthopaedic salvage has dramatically declined. Modern surgical interventions focus on correcting secondary structural deformities, preserving joint biomechanics, and reconstructing end-stage destruction in skeletally mature adolescents.

• Soft-Tissue Contracture Release: Indicated for fixed joint contractures refractory to aggressive medical therapy, serial casting, and physical therapy. Common procedures include percutaneous or open psoas tenotomy and adductor tenotomy for fixed hip flexion/adduction contractures, and fractional hamstring lengthening or posterior knee capsulotomy for fixed knee flexion contractures >15° to 20°. Care must be taken to prevent sciatic or peroneal nerve stretch injury during acute extension corrections.
• Synovectomy (Arthroscopic vs. Open): Indicated for localized, aggressive hypertrophic synovitis confined to a single joint (most commonly the knee or wrist) failing at least 6 months of optimized DMARD/biologic medical therapy and repeated corticosteroid injections, in the absence of advanced cartilage loss. Arthroscopic knee synovectomy offers lower morbidity, less postoperative stiffness, and earlier rehabilitation compared to open procedures. While synovectomy delivers substantial symptomatic relief and temporary reduction in joint effusions, it does not halt long-term disease progression.
• Guided Growth and Epiphysiodesis: Unilateral hyperemic knee synovitis stimulates adjacent femoral and tibial physes, causing true limb-length discrepancies and angular deformities (typically genu valgum). Temporary hemiepiphysiodesis using extra-periosteal tension-band plates (e.g., eight-plates or non-locking 2-hole plates) placed across the medial distal femoral and/or proximal tibial physis allows gradual correction of coronal mechanical axis deviation during growth. For projected leg-length discrepancies exceeding 2.0 to 2.5 cm at skeletal maturity, contralateral percutaneous epiphysiodesis is performed based on predictive growth remaining calculations (Green-Anderson or Moseley charts).
• Total Hip Arthroplasty (THA): Reserved for end-stage hip articular destruction, severe joint space obliteration, intractable pain, and profound functional impairment in adolescents and young adults approaching skeletal maturity. Severely diseased JIA hips present significant anatomical challenges, including profound acetabular dysplasia, medial protrusio, paper-thin cortices, excessive femoral anteversion, and an extremely narrow, straight, hypoplastic intramedullary femoral canal. Specialized miniature or custom CDH (congenital dislocation of the hip) femoral stems and small acetabular components (often <44 mm) are frequently required. Cementless acetabular fixation combined with highly crosslinked polyethylene or ceramic bearings is preferred. Extensive soft-tissue releases are necessary to restore functional motion.
• Total Knee Arthroplasty (TKA): Reserved for end-stage tricompartmental destruction and crippling pain. Characterized by severe flexion contractures, patellofemoral hypoplasia, diminished bone stock, and altered distal femoral geometry. Posterior-stabilized (PS) designs are commonly utilized to address posterior cruciate ligament attenuation and fixed deformities. Pre-resection soft-tissue balancing and distal femoral recutting must be performed cautiously to avoid neurovascular compromise.
• Cervical Spine Stabilization: Indicated for atlantoaxial instability with progressive neurologic deficits, myelopathy, or asymptomatic subluxation with an anterior atlanto-dens interval (AADI) >8 to 10 mm or posterior atlanto-dens interval (PADI / SAC) <13 to 14 mm on flexion radiographs. Posterior C1-C2 fusion (using transarticular screws or C1 lateral mass and C2 pedicle/pars screws with autologous bone graft) is performed with meticulous halo-vest or intraoperative navigation guidance.

Indications & Contraindications

• Indications for Guided Growth: Mechanical axis deviation in the coronal plane (genu valgum or varum with mechanical zone 2 or 3 malalignment) and at least 1.5 to 2.0 years of active skeletal growth remaining.
• Indications for Arthroplasty: Complete loss of articular cartilage (end-stage Kellgren-Lawrence grade 4 destruction), debilitating daily pain, and functional incapacitation (inability to ambulate or perform activities of daily living), ideally after near-closure of physes.
• Surgical Contraindications: Active systemic infection; active, uncontrolled systemic JIA flare (fever, pericarditis, cytopenias) or active Macrophage Activation Syndrome; uncorrected severe coagulopathy; and lack of skeletal maturity for elective primary joint replacement unless severe bilateral bony ankylosis has eliminated ambulation.

9. Outcome

Validated Patient-Reported Outcome Measures (PROMs): Assessment of treatment response in JIA utilizes validated composite instruments:

• American College of Rheumatology Pediatric (ACR Peds) Criteria: ACR Peds 30, 50, 70, and 90 define improvement of 30%, 50%, 70%, and 90% across at least 3 of 6 core set variables (physician global assessment, parent/patient global assessment, active joint count, limited joint count, ESR/CRP, and functional disability index) with no more than one variable worsening by >30%. Contemporary biologic trials achieve ACR Peds 70 responses in 65% to 80% of patients.
• Juvenile Arthritis Disease Activity Score (JADAS): Incorporates active joint count (JADAS-10, JADAS-27, or JADAS-71), physician global assessment, parent/child global assessment of well-being, and normalized ESR. JADAS provides a continuous score facilitating treat-to-target protocols.
• Childhood Health Assessment Questionnaire (CHAQ): Measures functional disability across 8 dressing, arising, eating, walking, hygiene, reach, grip, and activities domains (score 0 to 3). Modern early biologic interventions consistently reduce mean CHAQ scores toward zero (normal function).

Long-Term Joint Arthroplasty Survivorship: In juvenile patients undergoing primary total hip arthroplasty with modern cementless fixation and highly crosslinked polyethylene or ceramic-on-polyethylene bearings, 10-year implant survivorship ranges from 88% to 94%, with dramatic improvements in Harris Hip Scores, pain relief, and functional mobility. However, survivorship at 20 years drops to 60% to 75% due to aseptic loosening, extensive polyethylene wear, and severe acetabular bone loss, emphasizing the mandate to optimize medical preservation of the native joint.

10. Complications

Complications in JIA stem from uncontrolled chronic inflammatory synovitis, disease-modifying pharmacotherapy, and secondary surgical interventions on hypoplastic, osteopenic pediatric bones.

11. Pearls and Pitfalls

• The Asymptomatic Eye Pearl: Never wait for eye symptoms before ordering an ophthalmologic evaluation. The chronic anterior uveitis of oligoarticular JIA is silent, white, and painless. Irreversible visual loss, band keratopathy, and glaucoma can develop without a single red eye or subjective complaint. All newly diagnosed JIA patients must undergo immediate slit-lamp biomicroscopy.
• The “Normal ESR” Trap: Normal ESR and CRP do not exclude active JIA. Over 40% of children with active, destructive oligoarticular synovitis exhibit completely normal systemic inflammatory markers. Clinical examination and high-resolution ultrasound/MRI supersede serology.
• Airway Management Pearl: Every JIA patient scheduled for surgery requires careful evaluation of the cervical spine and temporomandibular joints. Limited mouth opening from TMJ ankylosis combined with asymptomatic atlantoaxial subluxation makes blind direct laryngoscopy dangerous. Always obtain dynamic cervical spine radiographs and coordinate with pediatric anesthesia for fiberoptic intubation when instability is suspected.
• Steroid Selection Pearl: When performing intra-articular knee injections, triamcinolone hexacetonide (THA) demonstrates significantly superior duration of remission and lower relapse rates compared with triamcinolone acetonide (TA). Utilize ultrasound guidance to confirm placement in the synovial sheath rather than periarticular subcutaneous tissues, avoiding skin depigmentation and subcutaneous fat atrophy.
• The Septic Arthritis Red Flag: A single hot, acutely swollen, exquisitely painful joint in a toddler with refusal to bear weight and high fever is septic arthritis until proven otherwise. Arthrocentesis with urgent synovial fluid cell count, Gram stain, and culture must precede empiric corticosteroid injection or immunosuppressive therapy.

12. Controversy

Top-Down vs. Step-Up Pharmacotherapy: A major debate in pediatric rheumatology centers on whether newly diagnosed polyarticular and extended oligoarticular JIA should be managed with early aggressive “top-down” biologic induction (immediate combination of anti-TNF and methotrexate) to exploit a hypothesized “window of opportunity” and alter long-term immunological trajectory, versus a conservative “step-up” approach requiring documented methotrexate failure before escalating to expensive biologic agents. Increasing evidence supports early biologic induction in high-risk patients with adverse prognostic markers (radiographic erosions, RF positivity, systemic involvement).

Optimal Timing of Total Joint Arthroplasty in Adolescents: Performing total hip or knee replacement in skeletally immature or adolescent patients remains controversial. Historically, surgeons delayed arthroplasty until late adulthood due to high revision rates and polyethylene wear. However, severe bilateral hip disease in JIA leads to pelvic retroversion, femoral hypoplasia, secondary spine deformities, and profound functional dependency. Current orthopaedic consensus supports early arthroplasty using modern highly crosslinked polyethylene or ceramic bearings when pain and mobility limitations prevent education and independent living, rather than prolonging crippling disability.

Biologic Discontinuation and De-escalation in Sustained Remission: Once a child achieves prolonged clinically inactive disease (greater than 6 to 12 months), controversy persists regarding the optimal strategy for medication withdrawal. Abrupt cessation of biologic agents carries a 30% to 50% relapse rate within 12 months. Ongoing clinical trials investigate predictive biomarkers (such as serum MRP8/14 / S100A8/A9 and high-sensitivity power Doppler ultrasound) to differentiate true immunological remission from subclinical synovitis prior to attempting gradual dose spacing or tapering.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Ringold S, Angeles-Han ST, Beukelman T et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019. doi:10.1002/acr.23870 [Level I: Systematic Review / Meta-Analysis]
• Onel KB, Horton DB, Lovell DJ et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis Care Res (Hoboken). 2022. doi:10.1002/acr.24839 [Level I: Systematic Review / Meta-Analysis]
• Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000. doi:10.1056/NEJM200003163421103 [Level I: Randomized Controlled Trial]
• Giannini EH, Brewer EJ, Kuzmina N et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med. 1992. doi:10.1056/NEJM199204163261602 [Level I: Randomized Controlled Trial]
• De Benedetti F, Brunner HI, Ruperto N et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012. doi:10.1056/NEJMoa1112802 [Level I: Randomized Controlled Trial]

15. Master Class Pro-Tip

When evaluating limb-length inequality and angular deformities in a child with unicompartmental or asymmetric knee JIA, distinguish hyperemic epiphyseal overgrowth from structural contracture before formulating an operative plan. In early active synovitis, the adjacent distal femoral physis experiences accelerated vascular perfusion, generating transient limb lengthening and progressive genu valgum. Do not rush to perform structural osteotomies while active synovitis persists. First achieve tight pharmacologic remission with pediatric rheumatology; if mechanical axis deviation persists with open physes, minimally invasive tension-band hemiepiphysiodesis (guided growth) will predictably harness remaining growth plates to realign the mechanical axis without the extensive morbidity, nonunion risk, and prolonged immobilization of formal corrective osteotomies.

Master Class Clinical Pearl: Juvenile Idiopathic Arthritis Deformity Management